Fig. 4: The intrinsic capacity of T-cells from B-NHL LN samples to induce cytotoxicity is comparable to that of healthy donor T-cells. | Blood Cancer Journal

Fig. 4: The intrinsic capacity of T-cells from B-NHL LN samples to induce cytotoxicity is comparable to that of healthy donor T-cells.

From: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Fig. 4

A Percentages cytotoxicity mediated by epcoritamab and CD3xCtrl (30 ng/mL) without addition of PBMCs in ND and RR DLBCL (n = 15), FL (n = 15), and MCL (n = 8) samples (median ± interquartile range), including patients who relapsed from or were refractory to CD20 therapy ( and , respectively). Statistical analysis was performed with Kruskal–Wallis and Dunn’s multiple comparisons test to compare epcoritamab with CD3xCtrl (*p < 0.05) and to compare epcoritamab-dependent cytotoxicity (subtracted with CD3xCTRL values) between subtypes (ns). B Ratio of CD4+ T helper cells (CD4+CD25) to CD8+ T-cells in DLBCL, FL, and MCL samples (Kruskal–Wallis with Dunn’s multiple comparisons test; *p < 0.05, **p ≤ 0.01) (median ± interquartile range). C PD-1 expression (MFI values normalized to expression on T-cells of internal healthy donor control) on CD4+ T-cells of DLBCL, FL, including PD-1 bright and dim populations, and MCL (Kruskal–Wallis with Dunn’s multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001) (median ± interquartile range). D Spearman’s correlation between CD3:Target ratio and cytotoxicity mediated by epcoritamab (30 ng/mL) (r = 0.63; ****p < 0.0001). E Lymph node T-cells of B-NHL patients isolated by magnetic-activated cell-sorting (MACS) showed similar percentages B-cell lymphoma cell line (WSU-DLCL2 and Daudi, left to right) cytotoxicity as T-cells isolated from healthy donor PB (mean ± SEM) (Mann–Whitney U-test; ns).

Back to article page